Glycomimetics Is A Biotechnology Company Based In Rockvillemarylandfounded In 2003The Company Focuses On Developing Glycobiology Based Therapies For Hematologic Cancers And Inflammatory Diseasesit Utilizes A Proprietary Chemistry Platform To Create Small Molecule Drugs Known As Glycomimeticsthe Leadership Teamled By Ceo Harout Semerjianhas Extensive Experience In Blood Cancer Therapeutics The Company S Lead Productuproleselanis In Pivotal Phase 3 Trials For Relapsed Refractory Acute Myeloid Leukemiaamland Phase 2 3 Trials For Newly Diagnosed Amluproleselan Is Recognized As A First In Class E Selectin Antagonist And Has Received Breakthrough Therapy And Fast Track Designations From The Fdaglycomimetics Is Also Developing Gmi 1687 For Sickle Cell Diseasethe Company Collaborates With Apollomics For Development And Commercialization Efforts In Greater Chinaprimarily Targeting Markets In The U Sand China
